Vivani Medical (NASDAQ:VANI – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider and Institutional Ownership
6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 46.4% of Vivani Medical shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Vivani Medical and VYNE Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivani Medical | 1 | 1 | 1 | 0 | 2.00 |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
Valuation and Earnings
This table compares Vivani Medical and VYNE Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivani Medical | N/A | N/A | -$23.49 million | ($0.45) | -2.60 |
| VYNE Therapeutics | $570,000.00 | 34.18 | -$26.48 million | ($0.78) | -0.75 |
Vivani Medical has higher earnings, but lower revenue than VYNE Therapeutics. Vivani Medical is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Vivani Medical and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivani Medical | N/A | -293.64% | -79.49% |
| VYNE Therapeutics | -4,646.14% | -74.86% | -63.87% |
Risk & Volatility
Vivani Medical has a beta of 3.17, suggesting that its share price is 217% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.
Summary
Vivani Medical beats VYNE Therapeutics on 7 of the 13 factors compared between the two stocks.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
